Endocrine Abstracts

We evaluated the volume of pituitary adenoma in patients treated with ocreotide LAR (SSLAR) prior to surgery.Materials and methods: Twenty-six patients (22 females and 4 males, mean age 57.5±15.0 years) were treated with SSLAR: 5 patients with microadenoma – during 6 months, and 21 patients with macroadenoma – during 12 months before surgery, as recommended by the Polish Society of Endocrinology. Concentration of hGH and IGF1 was evaluated...

Treatment of acromegalic patients with somatostatin analogues decreases hGH and IGF1 concentrations, improves general and metabolic conditions and decreases morbidity and mortality in these patients. We assessed the efficacy of octreotide LAR (SSLAR) in treating acromegalic patients following non-radical surgery of pituitary adenoma at a single centre.Materials and methods: At our Centre we follow 85 acromegalic patients who underwent surgery, including ...

Background: Somatostatin analogues are used to treat acromegaly patients who, following surgery, have not fulfilled cure criteria (hGH<2,5 ng/ml, IGF-1 below normal range for age and post-OGTT hGH <1,0 ng/ml). We evaluated the efficacy of Sandostatin LAR in managing such patients.Material and method: In our Clinic, 81 acromegaly patients (mean age 51.6±14.4 yrs) were registered over the years 1983-2005. Based on CT i MRI, macroadenoma and mi...

Introduction: In acromegalic patients the incidence of benign and malignant neoplasms, appears to be higher than that in the standard population. Our aim was to evaluate the incidence of tumours in acromegalic patients treated at our Department.Materials and methods: Over the years 1983–2008, 101 acromegalic patients (mean age 51.8±15.4 years), were diagnosed and treated in our Department. Pituitary macroadenoma and microadenoma were stated in ...